CVS Health Corporation $CVS Shares Bought by Adams Diversified Equity Fund Inc.

Key Points

• Adams Diversified Equity Fund increased its CVS Health stake by 175.5% in the fourth quarter, ending with 351,300 shares worth about $27.9 million.
• CVS continues to attract institutional interest, with hedge funds and other investors owning 80.66% of the company’s stock despite notable insider selling in recent months.
• Analysts remain largely bullish: CVS has a Moderate Buy rating with an average price target of $100.68, while the stock recently traded near its 52-week high after a strong earnings beat and upbeat 2026 guidance.

Adams Diversified Equity Fund Inc. grew its stake in shares of CVS Health Corporation (NYSE:CVS - Free Report) by 175.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 351,300 shares of the pharmacy operator's stock after purchasing an additional 223,800 shares during the quarter. CVS Health accounts for 0.9% of Adams Diversified Equity Fund Inc.'s investment portfolio, making the stock its 27th biggest position. Adams Diversified Equity Fund Inc.'s holdings in CVS Health were worth $27,879,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently modified their holdings of CVS. Sei Investments Co. lifted its stake in shares of CVS Health by 17.4% during the second quarter. Sei Investments Co. now owns 905,715 shares of the pharmacy operator's stock worth $62,474,000 after purchasing an additional 134,535 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of CVS Health by 1.2% in the second quarter. The Manufacturers Life Insurance Company now owns 1,121,377 shares of the pharmacy operator's stock worth $77,353,000 after acquiring an additional 13,329 shares in the last quarter. Treasurer of the State of North Carolina lifted its stake in shares of CVS Health by 1.3% in the second quarter. Treasurer of the State of North Carolina now owns 585,073 shares of the pharmacy operator's stock worth $40,358,000 after acquiring an additional 7,588 shares in the last quarter. HUB Investment Partners LLC lifted its stake in shares of CVS Health by 25.0% in the second quarter. HUB Investment Partners LLC now owns 15,063 shares of the pharmacy operator's stock worth $1,039,000 after acquiring an additional 3,011 shares in the last quarter. Finally, Alliancebernstein L.P. lifted its stake in shares of CVS Health by 8.0% in the second quarter. Alliancebernstein L.P. now owns 1,609,404 shares of the pharmacy operator's stock worth $111,017,000 after acquiring an additional 119,439 shares in the last quarter. Institutional investors and hedge funds own 80.66% of the company's stock.

Insider Activity at CVS Health

In other CVS Health news, Director Larry Robbins sold 1,983,538 shares of the company's stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total value of $187,345,164.10. Following the completion of the sale, the director directly owned 6,213,261 shares in the company, valued at $586,842,501.45. This represents a 24.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Tilak Mandadi sold 69,551 shares of the company's stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the sale, the executive vice president owned 10,133 shares of the company's stock, valued at $907,714.14. This trade represents a 87.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 3,441,551 shares of company stock valued at $323,703,977. Insiders own 0.85% of the company's stock.

CVS Health News Summary

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS is expanding access to GLP-1 weight-loss drugs, including bringing back Zepbound and loosening restrictions on newer oral therapies, which could improve customer engagement and prescription volume while supporting its broader healthcare platform. Is CVS (CVS) Using GLP-1 Access and AI Tools to Redefine Its Healthcare Moat?
• Positive Sentiment: The company is also pushing AI deeper into pharmacy, insurance, and care delivery operations, aiming to cut administrative burden, improve efficiency, and potentially widen margins over time. Healthy Returns: CVS Health executives on reducing health care's biggest pain points
• Positive Sentiment: CVS Health has launched Aetna Mental Health on Demand, which gives members faster access to care and shows the company is trying to strengthen service offerings across its insurance business. 5 Low Price-to-Book Stocks That Are Worth Buying in June
• Positive Sentiment: Recent coverage notes CVS at a 52-week high and highlights strong post-earnings momentum, while screening screens and “trending stock” mentions suggest investor interest remains elevated. CVS Health Corporation (CVS) Hit a 52 Week High, Can the Run Continue?
• Neutral Sentiment: CVS is also working with Fluency to move autonomous AI agents from pilot projects into production, but the financial impact is still early and not yet quantified. CVS is Using Fluency to Close Enterprise AI Deployment Gap
• Neutral Sentiment: News that Mass General Brigham and CVS are moving closer to a primary care partnership and that the stock is being heavily discussed by retail investors adds attention, but these items are not immediate earnings drivers. Mass General Brigham and CVS primary care partnership moves closer to reality
• Negative Sentiment: Musab Balbale’s departure adds some leadership turnover, though the market may view it as a limited issue unless more executive changes follow. Musab Balbale Departs CVS Health

Wall Street Analyst Weigh In

Several research analysts recently commented on CVS shares. HSBC boosted their price target on CVS Health from $83.00 to $85.00 and gave the stock a "hold" rating in a research note on Tuesday, May 5th. Leerink Partners reiterated an "outperform" rating and issued a $98.00 price target on shares of CVS Health in a research note on Thursday, March 5th. Truist Financial boosted their price target on CVS Health from $102.00 to $108.00 and gave the stock a "buy" rating in a research note on Monday, June 1st. DA Davidson boosted their price target on CVS Health from $80.00 to $100.00 and gave the stock a "buy" rating in a research note on Thursday, May 7th. Finally, Barclays boosted their price target on CVS Health from $101.00 to $106.00 and gave the stock an "overweight" rating in a research note on Tuesday, May 26th. Twenty-two investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, CVS Health currently has an average rating of "Moderate Buy" and an average price target of $100.68.

CVS Health Stock Up 1.4%

NYSE:CVS opened at $101.87 on Friday. The firm has a market capitalization of $129.98 billion, a PE ratio of 44.88, a price-to-earnings-growth ratio of 1.00 and a beta of 0.62. The stock has a 50 day moving average of $86.91 and a 200-day moving average of $80.78. CVS Health Corporation has a 52 week low of $58.50 and a 52 week high of $102.77. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78.

CVS Health (NYSE:CVS - Get Free Report) last posted its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, beating the consensus estimate of $2.21 by $0.36. The company had revenue of $100.43 billion during the quarter, compared to analyst estimates of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The business's revenue was up 6.2% compared to the same quarter last year. During the same period in the prior year, the company earned $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Analysts predict that CVS Health Corporation will post 7.44 EPS for the current year.

CVS Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, May 4th. Stockholders of record on Thursday, April 23rd were given a dividend of $0.665 per share. The ex-dividend date was Thursday, April 23rd. This represents a $2.66 annualized dividend and a dividend yield of 2.6%. CVS Health's payout ratio is currently 117.18%.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.